Authors
Latest:
Ibrutinib Plus Rituximab Demonstrate Efficacy in Phase 2 Trial of MCLPreetesh Jain, MD, PhD, discusses the efficacy and predictors of response with ibrutinib and rituximab in combination as treatment of patients with previously untreated mantle cell lymphoma.
Latest:
Apalutamide Maintains Health-Related Quality of Life in TITAN TrialThe addition of apalutamide to androgen deprivation treatment improved time to pain progression and other quality-of-life out­come measures in patients with metastatic castration-sensitive prostate cancer in the phase III TITAN trial.
Latest:
Palbociclib Shows Promise for Treatment of Brain Metastases Harboring CDK AlterationsAn interim analysis of the phase II study of palbociclib for the treatment of patients with brain metastases harboring CDK alterations was presented at the 2019 Society for NeuroOncology Annual Meeting by Priscilla K. Brastianos, MD, director of the central nervous system brain metastasis program, Massachusetts General Hospital.<br />
Latest:
Navigating Adverse Effects of JAK Inhibitors in Myeloproliferative NeoplasmsPrithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.
Latest:
Pembrolizumab in Non-Small Cell Lung CancerIn this article, Priyanka Bhateja, MD, and Neelesh Sharma, MD, PhD review the completed trials and ongoing clinical development of pembrolizumab in NSCLC.
Latest:
Ovarian Suppression for Younger Women With HR+ Breast CancerPrudence Francis, MD, discusses the SOFT trial, which examined suppression of ovarian function, and the impact it could have on the future treatment of women under 35 with HR+ breast cancer.
Latest:
The Potential Roles of Immunotherapy in NSCLC TreatmentPuneeth Iyengar, MD, PhD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the two potential roles immunotherapy could play in the treatment of NSCLC.
Latest:
Ceritinib For Lung Cancer TreatmentQuincy Chu, MD, associate professor, medical oncologist, University of Alberta, discusses the development of ceritinib.
Latest:
Dr. R. Michael Tuttle on New Horizons for Radioactive Iodine TreatmentR. Michael Tuttle, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, talks about the new horizons for radioactive iodine treatment in thyroid cancer.
Latest:
Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain MetastasesRachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.
Latest:
Investigating TTFields for Treatment of Newly Diagnosed GlioblastomaRachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields, an antimitotic treatment.
Latest:
Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma SubtypesProlonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.
Latest:
Clinical Investigation Into Antibody With Activity Against SSTR2 and CD3 Moves ForwardPositive preliminary data from the phase 1 DUET-1 study examining XmAb18087 in patients with neuroendocrine tumors demonstrated promising safety and efficacy findings.
Latest:
The Investigation of Immune Checkpoint Blockades in Small Cell Lung CancerRaffaele Califano, MD, consultant in medical oncology, The Christie Clinic, University Hospital of South Manchester, discusses the recent investigations into the use of immune checkpoint blockades in small cell lung cancer.
Latest:
Treating a Patient With HER2-Negative Chemotherapy-Resistant mBCRagene Rivera, MD, medical oncologist, Texas Oncology-El Paso Cancer Treatment Center, discusses the next treatment steps for a patient with HER2-negative chemotherapy-resistant metastatic breast cancer.
Latest:
Evaluating Prognosis of Patients With Ocular MelanomaRagini Kudchadkar, MD, discusses the overall prognosis of patients with ocular melanoma.
Latest:
How Care for Merkel Cell Carcinoma Has Been Revolutionized in Recent YearsRagini R. Kudchadkar, MD, assistant professor, department of Hematology and Medical Oncology, Emory University School of Medicine, discusses how care for Merkel cell carcinoma has been revolutionized in recent years.
Latest:
Post-Prostatectomy Radiation and Its Impact on Reducing Prostate Cancer MortalityRahul Tendulkar, MD, associate, Cleveland Clinic, discusses findings of a recent study looking at post-prostatectomy radiation and its impact on prostate cancer mortality.
Latest:
Managing Pneumonitis Following Immune Checkpoint Inhibition in Kidney CancerRaja E. Abdulnour, MD, discusses modern management strategies for pneumonitis induced by treatment with immune checkpoint inhibitors in patients with kidney cancer.
Latest:
Anti-CD20 Agent Yields High Responses in Follicular LymphomaRajat Bannerji, MD, PhD, discusses the safety and efficacy results of REGN1979 in the follicular lymphoma cohort enrolled in the phase I study of patients with relapsed/refractory B-Cell non-Hodgkin lymphoma who were previously treated with an anti-CD20 agent.
Latest:
Future Directions for Elderly Patients With Relapsed/Refractory AMLRajneesh Nath, MD, discusses what is in store regarding treatment for elderly patients with relapsed/refractory acute myeloid leukemia.
Latest:
An Overview of an Immuno-Oncology Panel for Standardized Profiling of Immune StatusRalf Huss, MD, Chief Medical Officer of Definiens, discusses a new immuno-oncology panel introduced by Definiens during the The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. The goal of the panel is to standardize the immunoprofiling of tumors to better predict response to immuno-oncology treatment.
Latest:
Dr. Ramaprasad Srinivasan on the Complex Heterogeneity of Kidney CancerSrinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.
Latest:
Leveraging Biomarkers to Advance Endometrial Cancer CareRamez N. Eskander, MD, discusses additional targetable biomarkers that could be addressed in a similar combination as what was seen in the phase 3 NRG-GY018/KEYNOTE-868 trial with standard of care chemotherapy.
